Oregon Health and Science University Center for Women's Health

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Retrieved on: 
Monday, March 20, 2023
Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Gene, Lineage, Visual impairment, Retinal, AMD, Foundation Fighting Blindness, University Medical Center, Roche, Geographic atrophy, Oregon Health and Science University Center for Women's Health, Physician, TASE, NYSE American, Lineage Cell Therapeutics, Therapy, Oregon Health & Science University, Hadassah Medical Center, Pharmaceutical industry, Genentech, Ophthalmology, Patient

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit , organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 ( OpRegen ), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit , organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The meeting will be held April 21st, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans, LA.
  • RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD).
  • The 2023 Retinal Cell and Gene Therapy Innovation Summit , "Defining the Preclinical to Clinical Roadmap" will feature presentations that emphasize clinical trial design for gene and cell-based therapies.

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Retrieved on: 
Saturday, March 18, 2023
American Academy of Dermatology, Oregon Health and Science University Center for Women's Health, Clinical trial, Quality of life, American Academy, Atopic dermatitis, Regeneron Pharmaceuticals, Patient, AAD, Annual general meeting, Itch, Human, Skin, Vaccine, Pharmaceutical industry, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints.
  • The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • There were significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related quality of life.
  • The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis.

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023
DNA, American Society for Reproductive Medicine, Human, Pregnancy, MRTS, University, Life, Reproductive technology, Mitochondrion, Embryo, Infertility, National Authority for Remote Sensing and Space Sciences, Cell, RNA, Cytoplasm, Fertilisation, Female, IVF, Fertility, A-DNA, Patient, Risk, Child, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, MST, Organelle, Mitochondrial disease, Health, Safety, Egg, Vaccine, Birth control

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023
DNA, American Society for Reproductive Medicine, Human, Pregnancy, MRTS, University, Life, Reproductive technology, Mitochondrion, Embryo, Infertility, National Authority for Remote Sensing and Space Sciences, Cell, RNA, Cytoplasm, Fertilisation, Female, IVF, Fertility, A-DNA, Patient, Risk, Child, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, MST, Organelle, Mitochondrial disease, Health, Safety, Egg, Vaccine, Birth control

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

CRAACO®: Clinical Research as a Care Option Organized by the Conference Forum Announces Keynote and Key Topics for the 7th Annual Meeting

Retrieved on: 
Monday, March 6, 2023
MD, Health Affairs, MBA, Research Triangle Park, Oregon Health & Science University, Raleigh–Durham International Airport, Research, Clinical trial, Research program, Wake Forest University, Patient, Oregon Health and Science University Center for Women's Health, Health, Conference, Atrium Health Wake Forest Baptist, Clinical research, Pharmaceutical industry, Nursing

NEW YORK, March 6, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, with the 2023 keynote and key topics. The meeting will take place May 22-23, 2023 at the Sheraton Imperial Hotel Raleigh-Durham Airport at Research Triangle Park, in Raleigh-Durham, NC.

Key Points: 
  • The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, May 22-23, 2023 in Raleigh-Durham, NC, with the 2023 keynote and key topics.
  • NEW YORK, March 6, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced the launch of the 7th annual CRAACO®: Clinical Research as a Care Option conference, with the 2023 keynote and key topics.
  • The meeting will take place May 22-23, 2023 at the Sheraton Imperial Hotel Raleigh-Durham Airport at Research Triangle Park, in Raleigh-Durham, NC.
  • "CRAACO is the only conference that examines how we can integrate care and research to give many more patients access to clinical research," said Valerie Bowling, Executive Director, Conference Forum.

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

Retrieved on: 
Saturday, March 4, 2023
Research, Heart failure, Oxford Handbook of Clinical Medicine, Conference, Cytokinetics, Oregon Health and Science University Center for Women's Health, LVEF, American College, SAN, Disease, NYHA, Conference call, Cohort, Host, Research and development, Cardiology, Clinical study design, LVOT, New York Heart Association Functional Classification, Medical device, Pharmaceutical industry, Patient, HCM

SOUTH SAN FRANCISCO, Calif., March 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that positive results from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), were presented at the American College of Cardiology 72nd Annual Scientific Session (ACC.23). Additionally, 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) were also presented at the meeting.

Key Points: 
  • Additionally, 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) were also presented at the meeting.
  • At 10 weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66% (p
  • The live audio of the conference call can also be accessed by telephone by registering in advance at the following link: Cytokinetics ACC.23 Conference Call .
  • An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.

Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study

Retrieved on: 
Wednesday, March 1, 2023
Oncology, Health, Surgery, Clinical Trials, Research, Science, Biotechnology, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, Biological Dynamics of Forest Fragments Project, Doctor of Philosophy, Quality of life, MD, Survival, Diagnosis, PDAC, Sheppard, Pancreatic cancer, Disease, Partnership, Biomarker, Pancreas, Patient, DRS, Sears, Pancreatic cyst, Medical genetics, Neoadjuvant therapy, OHSU, Blood, Biology, FACS, Pharmaceutical industry

Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.

Key Points: 
  • Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.
  • The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations.
  • The ExoVita Pancreas assay significantly improves the care of patients at high risk for pancreatic cancer through earlier detection.
  • “We have a long-standing relationship with Oregon Health & Science University and look forward to collaborating to evaluate the clinical validity of our ExoVita Pancreas test,” said Paul Billings, MD, PhD, CEO of Biological Dynamics.

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023
Netherlands Cancer Institute, Immunotherapy, Cancer, Prostate cancer, DNA, University, Principal, Basic research, SAB, VISTA, Stomach cancer, Associate, Core, Fred Hutchinson Cancer Research Center, Research, University of Washington School of Medicine, Gastrointestinal cancer, Pacific Northwest, United States Department of Defense, National Cancer Institute, Biomarker, LAPS, Knight Cancer Institute, Patient, Esophageal cancer, Trial of the century, IDeA Networks of Biomedical Research Excellence, Cell, Clinical Cancer Research, OHSU, Ponce Health Sciences University, AACR, Oregon Health & Science University, United States Air Force Scientific Advisory Board, Oregon Health and Science University Center for Women's Health, Medical director, Development of the human body, ASCO, Gastrointestinal tract, Prostate, Medical device, Medical imaging, Kineta

to the company’s immuno-oncology focused Scientific Advisory Board (SAB).

Key Points: 
  • to the company’s immuno-oncology focused Scientific Advisory Board (SAB).
  • Dr. Chalabi and Dr. Yu will join Kineta’s SAB that includes Lisa Coussens, Ph.D., Michael Curran, Ph.D. and Patricia LoRusso, D.O.
  • “We are delighted to have Dr. Chalabi and Dr. Yu join Kineta's Scientific Advisory Board,” stated Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta.
  • “These experts will greatly complement our existing SAB and guide the company as we advance clinical development of KVA12123 in patients with advanced solid tumors.”
    Myriam Chalabi, M.D.

Louisiana Hospitals Hit with Class-Action Lawsuits over Sharing Patients' Data

Retrieved on: 
Tuesday, February 14, 2023
West Jefferson Medical Center, Health, Hospital, Children's Hospital, Women's health, Lawyer, East Jefferson General Hospital, Prescription, Patient, Katz, LCMC Health System, Arthralgia, Knowledge, Oregon Health and Science University Center for Women's Health, Touro, University Medical Center New Orleans, Name, HHK, Medical device

NEW ORLEANS, Feb. 14, 2023 /PRNewswire/ -- Two of the largest hospital networks in Louisiana have been using a tracking code embedded deep in their websites that shares sensitive patient data without the patients' knowledge or consent, according to class-action lawsuits filed by Herman Herman & Katz trial lawyers.

Key Points: 
  • Known as Meta Pixel, the computer code created by the company that owns Facebook and Instagram potentially analyzed, gathered and shared the sensitive medical data of hundreds of thousands of patients, the lawsuits allege.
  • These victims were patients within the LCMC Health Systems network of hospitals in the New Orleans area and Willis-Knighton Health System facilities in northwest Louisiana, according to the lawsuits.
  • According to the lawsuits, use of the Meta Pixel in healthcare settings violates various provisions of Louisiana law which generally prohibit the sharing of personal health information with a third party without patient consent.
  • Our Louisiana personal injury lawyers are here to aggressively pursue justice on your behalf and help you get back on your feet.

FDA Clears 'Selux NGP System' for Rapid Antibiotic Susceptibility Testing

Retrieved on: 
Thursday, January 19, 2023
Biomedical Advanced Research and Development Authority, Infection, NGP, Development, Office of Inspector General, U.S. Department of Health and Human Services, AMR, Administration, CLSI, Regulation of tobacco by the U.S. Food and Drug Administration, Doctor of Pharmacy, FDA, Oregon Health & Science University, Death, BARDA, Food, ASPR, Patient, Oregon Health Plan, Cancer, HHS, Oregon Health and Science University Center for Women's Health, AST, Vaccine, Pharmaceutical industry, FIDSA

The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel.

Key Points: 
  • The FDA clearance is for Selux Diagnostics' in vitro antimicrobial resistance test, which determines a bacteria's susceptibility to 14 specific antimicrobial agents on the Selux Gram-Positive Panel.
  • Selux's NGP Gram-Negative panel is currently under review by the FDA.
  • "This clearance represents a significant advance in infectious disease care and the fight to address antibiotic resistance.
  • Our groundbreaking Selux NGP System holds the potential to save lives and decrease overreliance on broad-spectrum antibiotics, a key factor contributing to the rise of superbugs.